Nightingale Health Oyj Stock

Equities

HEALTH

FI4000490875

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Helsinki 11:23:10 2024-05-15 am EDT 5-day change 1st Jan Change
1.6 EUR -1.84% Intraday chart for Nightingale Health Oyj -13.28% +43.37%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.7M 5.09M Sales 2025 * 8.7M 9.42M Capitalization 98.36M 107M
Net income 2024 * -16M -17.33M Net income 2025 * -16M -17.33M EV / Sales 2024 * 6.91 x
Net cash position 2024 * 65.9M 71.37M Net cash position 2025 * 52.2M 56.53M EV / Sales 2025 * 5.31 x
P/E ratio 2024 *
-6.04 x
P/E ratio 2025 *
-6.04 x
Employees 81
Yield 2024 *
-
Yield 2025 *
-
Free-Float 53.93%
More Fundamentals * Assessed data
Dynamic Chart
Finland’s Nightingale Health Plots US Expansion MT
Nightingale Health to Establish A Laboratory in the United States CI
Nightingale Health and the Englander Institute for Precision Medicine At Weill Cornell Medicine Sign A Letter of Intent in Which the Parties Agree to Collaborate on the Adoption of Nightingale Health's Proprietary Technology in Healthcare and Medical Research in the United States CI
Nightingale Health Secures Blood Analysis Contract with Kaiser Foundation MT
Nightingale Health Enters into Agreement to Analyze 50,000 Blood Samples with Kaiser Foundation Health Plan, Inc CI
Nightingale Health Closes Purchase of Japan's Welltus MT
Nightingale Health Oyj completed the acquisition of Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited. CI
Nightingale Health plc Enters into an Agreement in Which It Will Analyze Blood Samples from Uganda's General Population Cohort CI
Finland-based Nightingale Health to Buy Japan's Welltus MT
Transcript : Nightingale Health Oyj, H1 2024 Earnings Call, Mar 07, 2024
Nightingale Health Oyj Reports Earnings Results for the Half Year Ended December 30, 2023 CI
Nightingale Health Oyj agreed to acquire Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited. CI
Singaporean Regulator Approves Nightingale Health's Blood Analysis Technology MT
Nightingale Health Oyj Receives Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore CI
Nightingale Health Lands Five New Health Risk Detection Patents in Finland MT
More news
1 day+1.23%
1 week-10.57%
Current month-7.82%
1 month+28.91%
3 months+48.92%
6 months+40.31%
Current year+47.85%
More quotes
1 week
1.59
Extreme 1.59
1.85
1 month
1.31
Extreme 1.31
2.00
Current year
0.98
Extreme 0.982
2.00
1 year
0.80
Extreme 0.797
2.00
3 years
0.80
Extreme 0.797
5.95
5 years
0.80
Extreme 0.797
6.75
10 years
0.80
Extreme 0.797
6.75
More quotes
Managers TitleAgeSince
Founder - 01-12-31
Founder 48 01-12-31
Founder - 01-12-31
Members of the board TitleAgeSince
Director/Board Member 59 20-12-16
Chairman 61 20-12-31
Director/Board Member 61 14-12-31
More insiders
Date Price Change Volume
24-05-15 1.6 -1.84% 47 006
24-05-14 1.63 -1.21% 77,753
24-05-13 1.65 -7.82% 114,644
24-05-10 1.79 -2.98% 68,806
24-05-08 1.845 -2.89% 61,567

Delayed Quote Nasdaq Helsinki, May 15, 2024 at 04:42 am EDT

More quotes
Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Company’s subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
1.63 EUR
Average target price
1.6 EUR
Spread / Average Target
-1.84%
Consensus
  1. Stock Market
  2. Equities
  3. HEALTH Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW